We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Celecoxib Added to the Mood Stabilizer to Treat Acute Mania: ARandomized, Triple-Blind, Placebo-Controlled Trial Main title: Celecoxib Added to the Mood Sabilizer to Treat Acute Mania.
- Authors
Faridhosseini, Farhad; Talayi, Ali; Shahini, Najmeh; Eslamzadeh, Mahboobeh; Ahrari, Samira; Poorgholami, Meysam; Majid Khadem Rezaeian
- Abstract
Background: The inflammatory processes of brain contribute to the aetiopathogenesis of acute mania. Cyclooxygenase-2 (COX-2) inhibitors such as celecoxib reduce the production of pro-inflammatory cytokines. The purpose of the present study is to assess the efficacy of celecoxib in treating acute mania. Methods: A triple-blind and placebo-controlled trial was conducted for 58 patients who met the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) criteria for acute mania screening to participate in the trial used by the study. Twenty three patients were assigned to a study group and were given valprovate sodium 200 mg /BD as well as celecoxib 400 mg/day (200 mg BID). The control group included 22 patients who were administered with valprovate sodium 200 mg /BD and placebo. The patients were assessed by a psychiatrist at baseline 0, after 9, 18 and 28 days from starting to receive the medication .The data were analyzed using the Statistical Package for Social Sciences (SPSS )version 11.5,.the two-way repeated measure analysis of the variance, the Fisher's exact test, and the t-test .P≤0.05 was considered to be statistically significant. Results: A total of 58 patients were screened, and 45 patients were randomized. Most of the participants in celecoxib group were male (55%), and most of them in the placebo group were female (75%). There were no statistically significant differences among the groups regarding the number of episodes, gender, marital status, the past medical history and the family history (P value ≥0.05). A significant difference was observed in the change of the scores on the Young mania rating scale (YMRS) at week 4, compared with the baseline in the groups of patients (P value= 0.04). Conclusion: The results of the current study suggested that celecoxib can be an effective adjuvant agent in managing patients with acute mania and that anti-inflammatory therapies should be further investigated in treating patients.
- Subjects
CELECOXIB; MOOD stabilizers; MANIA; FISHER exact test; BLIND experiment
- Publication
Iranian Journal of Psychiatry & Behavioral Sciences / Progress in Psychiatry & Behavioral Sciences, 2018, p173
- ISSN
1735-8639
- Publication type
Article